Impact of risk-adapted therapy for pediatric Hodgkin lymphoma on long-term risk of morbidity

Analysis of the Childhood Cancer Survivor Study found that risk-adapted therapy for pediatric Hodgkin lymphoma has resulted in a significant reduction in serious long-term outcomes.